Dyslipoproteinemia during the active course of systemic lupus erythematosus in association with anti-double-stranded DNA (anti-dsDNA) antibodies

被引:9
作者
Kashef, Sara [1 ]
Ghaedian, Mohammad Mehdi
Rajaee, Akbar
Ghaderi, Abbas
机构
[1] Shiraz Univ Med Sci, Dept Pediat, Div Immunol & Allergy, Shiraz, Iran
[2] Shiraz Univ Med Sci, Dept Internal Med, Div Rheumatol, Shiraz, Iran
[3] Shiraz Univ Med Sci, Dept Immunol, Shiraz Med Sch, Shiraz, Iran
关键词
SLE; dyslipoproteinemia; anti-double-stranded DNA antibody; HIGH-DENSITY-LIPOPROTEIN; TUMOR-NECROSIS-FACTOR; APOLIPOPROTEIN A1; DISEASE-ACTIVITY; CHOLESTEROL; LIPASE; AUTOANTIBODIES; PLASMA;
D O I
10.1007/s00296-006-0195-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Dyslipoproteinemia is common in lupus patients. In this study, we investigated the pattern of dyslipoproteinemia in the course of active systemic lupus erythematosus (SLE) in possible association with anti-double-stranded DNA (anti-dsDNA) antibodies. Forty-six lupus patients under 45 years old who fulfilled the American College of Rheumatology revised criteria for the classification of SLE were selected. The exclusion criteria were renal failure, nephrotic syndrome, thyroid or liver disease, diabetes mellitus, obesity, pregnancy and taking drugs that induce dyslipidemia. Disease activity was measured by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Comparison of the lipid profiles, between active and inactive groups determined high levels of serum TG and VLDL and low levels of serum HDL in active group in comparison with inactive group(P < 0.05). The results indicated that the levels of TG and VLDL were significantly elevated in the patients with positive anti-dsDNA (P < 0.05). Although, the mean of serum HDL levels was also lower in patients with positive anti-dsDNA, the difference was not significant. This pattern of dyslipoproteinemia in active SLE may be associated with the autoimmune mechanisms especially in relation to the presence of anti-dsDNA antibodies.
引用
收藏
页码:235 / 241
页数:7
相关论文
共 30 条
[1]  
Abe H, 2001, J RHEUMATOL, V28, P990
[2]   SYSTEMIC LUPUS-ERYTHEMATOSUS IN CHILDHOOD PRESENTING AS HYPERLIPOPROTEINEMIA [J].
ALVERSON, DC ;
CHASE, HP .
JOURNAL OF PEDIATRICS, 1977, 91 (01) :72-75
[3]   INHIBITION OF LIPOPROTEIN-LIPASE ACTIVITY BY A MONOCLONAL IMMUNOGLOBULIN IN AUTOIMMUNE HYPERLIPIDEMIA [J].
BEAUMONT, JL ;
BERARD, M ;
ANTONUCCI, M ;
DELPLANQUE, B ;
VRANCKX, R .
ATHEROSCLEROSIS, 1977, 26 (01) :67-77
[4]  
BEUTLER BA, 1985, J IMMUNOL, V135, P3969
[5]   DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].
BOMBARDIER, C ;
GLADMAN, DD ;
UROWITZ, MB ;
CARON, D ;
CHANG, CH .
ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640
[6]   Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies [J].
Borba, EF ;
Bonfa, E .
LUPUS, 1997, 6 (06) :533-539
[7]  
Borba EF, 2000, ARTHRITIS RHEUM, V43, P1033, DOI 10.1002/1529-0131(200005)43:5<1033::AID-ANR11>3.0.CO
[8]  
2-B
[9]   Serum IL-6, TNFα, p55 srTNFα, p75 srTNFα, srIL-2α levels and disease acitivity in systemic lupus erythematosus [J].
Davas, EM ;
Tsirogianni, A ;
Kappou, I ;
Karamitsos, D ;
Economidou, I ;
Dantis, PC .
CLINICAL RHEUMATOLOGY, 1999, 18 (01) :17-22
[10]  
DELGADO AJ, 2002, ARTHRITIS RHEUM, V46, P2686, DOI DOI 10.1371/JOURNAL.PONE.0186513